Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Moon Jae Chung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5920-8549; OpenAlex author ID A5046089418, A5114013750. Sources: OpenAlex.

Their work

Papers
56 (first author 11, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2013: 5 papers · 2014: 5 papers · 2015: none · 2016: 5 papers · 2017: 5 papers · 2018: 4 papers · 2019: 3 papers · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers · 2023: 2 papers · 2024: 5 papers · 2025: 3 papers · 2026: 3 papers

Papers 50 of 56

  1. FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Co-author DOI 10.1016/j.tranon.2026.103085↗
  2. Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study. Last author DOI 10.1136/gutjnl-2025-335863↗
  3. Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3348/kjr.2025.1394↗
  4. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
  5. Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02374-y↗
  6. Laparoscopic omentopexy as a spacer for carbon-ion radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.14701/ahbps.25-044↗
  7. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  8. Convolutional neural network model for automatic recognition and classification of pancreatic cancer cell based on analysis of lipid droplet on unlabeled sampl… Co-author DOI 10.1016/j.cmpb.2024.108041↗
  9. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1038/s41598-024-52909-4↗
  10. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
  11. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  12. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. Co-author DOI 10.1210/clinem/dgac728↗
  13. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Co-author DOI 10.3389/fonc.2023.1206565↗
  14. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34144↗
  15. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Co-author DOI 10.3390/cancers14010236↗
  16. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Co-author DOI 10.3390/cancers14051244↗
  17. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  18. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  19. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  20. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jgh.15265↗
  21. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. First author DOI 10.1177/0284185120917118↗
  22. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08898-y↗
  23. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. First author DOI 10.2196/21088↗
  24. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-020-04051-x↗
  25. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  26. Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001687↗
  27. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  28. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  29. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Co-author DOI 10.5009/gnl18419↗
  30. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Co-author DOI 10.1002/cam4.2210↗
  31. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Co-author DOI 10.1080/01635581.2019.1597906↗
  32. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001319↗
  33. Long-term patterns of fasting blood glucose levels and pancreatic cancer incidence. Co-author DOI 10.1007/s10552-017-0988-6↗
  34. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Co-author DOI 10.1038/s41598-018-21823-x↗
  35. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i11.421↗
  36. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i12.505↗
  37. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  38. The Significance of the Prognostic Nutritional Index for All Stages of Pancreatic Cancer. First author DOI 10.1080/01635581.2016.1250921↗
  39. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… First author DOI 10.1097/md.0000000000005702↗
  40. Clinical characteristics of second primary pancreatic cancer. Co-author DOI 10.1371/journal.pone.0179784↗
  41. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. First author DOI 10.5009/gnl16526↗
  42. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Co-author DOI 10.1016/j.dld.2015.12.006↗
  43. Visceral Obesity is Associated with Poor Prognosis in Pancreatic Adenocarcinoma. First author DOI 10.1080/01635581.2016.1134600↗
  44. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Co-author DOI 10.1097/md.0000000000003607↗
  45. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.3349/ymj.2016.57.5.1124↗
  46. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Co-author DOI 10.5009/gnl15186↗
  47. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00262-014-1566-3↗
  48. Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. First author DOI 10.1097/mpa.0000000000000163↗
  49. Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanc… Co-author DOI 10.1159/000375402↗
  50. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. First author DOI 10.5009/gnl.2014.8.1.109↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seungmin Bang · 48 shared papers, 2013–2026 · strength 5.05
  2. Jeong Youp Park · 48 shared papers, 2013–2026 · strength 5.03
  3. Seung Woo Park · 45 shared papers, 2013–2025 · strength 4.44
  4. Hee Seung Lee · 34 shared papers, 2016–2025 · strength 4.00
  5. Si Young Song · 43 shared papers, 2013–2024 · strength 3.84
  6. Jung Hyun Jo · 26 shared papers, 2014–2026 · strength 3.51
  7. Huapyong Kang · 13 shared papers, 2014–2024 · strength 1.28
  8. Ho Kyoung Hwang · 8 shared papers, 2013–2026 · strength 1.08
  9. Jiyoung Keum · 7 shared papers, 2020–2025 · strength 1.07
  10. Chang Moo Kang · 8 shared papers, 2013–2025 · strength 1.01
  11. Mi‐Suk Park · 7 shared papers, 2017–2024 · strength 0.85
  12. Jee Hoon Kim · 3 shared papers, 2024–2026 · strength 0.65
  13. Jae Bock Chung · 12 shared papers, 2013–2017 · strength 0.65
  14. Seung‐seob Kim · 4 shared papers, 2020–2024 · strength 0.56
  15. Kyung In Shin · 3 shared papers, 2024–2025 · strength 0.56
  16. Jae Hee Cho · 3 shared papers, 2022–2025 · strength 0.53
  17. Sung Ill Jang · 3 shared papers, 2022–2025 · strength 0.53
  18. Dawoon Jung · 4 shared papers, 2018–2023 · strength 0.51
  19. Sung‐In Jang · 2 shared papers, 2023–2026 · strength 0.46
  20. Sang Hoon Lee · 5 shared papers, 2016–2024 · strength 0.46
  21. Woo Jung Lee · 6 shared papers, 2013–2022 · strength 0.46
  22. Jin Su Kim · 2 shared papers, 2024–2025 · strength 0.38
  23. In Rae Cho · 5 shared papers, 2013–2021 · strength 0.37
  24. Man Deuk Kim · 2 shared papers, 2021–2026 · strength 0.37
  25. Joon Ho Kwon · 2 shared papers, 2021–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.